Change in vital signs after fingolimod initiation in patients with multiple sclerosis: the possible need for 24 h monitoring

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-2125|80|3|607-608

ISSN： 0306-5251

Source： BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol.80, Iss.3, 2015-09, pp. : 607-608

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Persistent Headache in Patients With Multiple Sclerosis Starting Treatment With Fingolimod

By  

HEADACHE, Vol. 55, Iss. 4, 2015-04 ,pp. : 578-579

John Wiley & Sons Inc

Access to resources Recommend Favorite

Fingolimod efficacy in multiple sclerosis associated with Sjogren syndrome

By  

ACTA NEUROLOGICA SCANDINAVICA (ELECTRONIC), Vol. 131, Iss. 2, 2015-02 ,pp. : 140-143

John Wiley & Sons Inc

Access to resources Recommend Favorite

Switch to natalizumab versus fingolimod in active relapsing–remitting multiple sclerosis

By  

ANNALS OF NEUROLOGY, Vol. 77, Iss. 3, 2015-03 ,pp. : 425-435

John Wiley & Sons Inc

Access to resources Recommend Favorite

Long‐term cardiac safety and tolerability of fingolimod in multiple sclerosis: A postmarketing study

By  

JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol. 55, Iss. 10, 2015-10 ,pp. : 1131-1136

John Wiley & Sons Inc

Access to resources Recommend Favorite

Vital signs

By Brettell Rachel  

British Journal of General Practice, Vol. 63, Iss. 614, 2013-09 ,pp. : 491-491

Royal College of General Practitioners

Access to resources Recommend Favorite